The dosage for tirzepatide follows a fixed FDA-approved escalation schedule: starting at 2.5mg weekly and increasing every four weeks up to a maximum of 15mg. This complete dosage guide covers what each dose achieves clinically, when to slow or pause escalation, how dosing differs between weight management and type 2 diabetes, and what drug interactions require attention. The 2.5mg starting phase — what to expect week by week — is covered separately in our dedicated guide: Tirzepatide 2.5mg Starting Dose: What to Expect Week by Week.
How Tirzepatide Dosing Works: The Core Principles
Tirzepatide is a dual GLP-1 and GIP receptor agonist administered as a once-weekly subcutaneous injection. The dosage for tirzepatide is not calculated by body weight — instead, all patients follow the same fixed-dose escalation protocol regardless of starting weight, though the clinical response (percentage of body weight lost) varies significantly by individual.
The tirzepatide dosage escalation schedule serves two purposes: first, it allows the gastrointestinal system to adapt to progressive gastric slowing, reducing nausea, vomiting, and diarrhea severity at each new dose level. Second, it ensures steady-state plasma concentration is reached before advancing — tirzepatide has a half-life of approximately 5 days, requiring roughly 4–5 weeks to reach full steady state at any given dose.
Both brand names contain tirzepatide at identical doses. Zepbound is FDA-approved for chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related comorbidity. Mounjaro is FDA-approved for type 2 diabetes management. Using Mounjaro for obesity without diabetes is considered off-label prescribing. The dosing schedule in this guide applies to both products identically.
Tirzepatide Dosage Schedule: All Six Dose Levels Explained
The complete tirzepatide dosage schedule below summarises the full FDA-approved escalation pathway with clinical benchmarks at each dose tier from the SURMOUNT trial programme. The 2.5mg starting phase is included for completeness — for the full week-by-week breakdown of that phase, see our dedicated 2.5mg guide.
| Dose | Phase & Duration | Key Clinical Notes |
|---|---|---|
| 2.5 mg | Starting dose · 4 weeks (mandatory) | Tolerability only — not a therapeutic weight loss dose. GI adaptation begins. Full week-by-week breakdown: Starting Dose Guide → |
| 5 mg | Escalation 1 · 4 wks min | First therapeutic dose. SURMOUNT-1: −15.0% body weight at 72 weeks. Meaningful weight loss begins. Some patients reach long-term maintenance here. |
| 7.5 mg | Escalation 2 · 4 wks min | GI adaptation typically milder than at the starting dose phase. Significant food noise reduction for most patients at this level. |
| 10 mg | Therapeutic · 4 wks min | SURMOUNT-1: −19.5% body weight at 72 weeks. Most common maintenance dose in clinical practice. Near-maximum efficacy at this level. |
| 12.5 mg | Therapeutic · 4 wks min | Bridge dose between 10mg and 15mg. Some protocols skip this level if 10mg is well-tolerated. |
| 15 mg | Max / Maintenance · Ongoing | Maximum approved dose. SURMOUNT-1 primary endpoint: −20.2% body weight at 72 weeks. Not all patients need to reach this dose. |
What Each Tirzepatide Dose Actually Achieves: Efficacy by Tier
Not all tirzepatide doses contribute equally to total weight loss. Understanding the dosage for tirzepatide at each tier is essential for setting realistic expectations. The SURMOUNT-1 trial enrolled over 2,500 adults with obesity (no type 2 diabetes) and randomised them to 5mg, 10mg, or 15mg tirzepatide, or placebo, for 72 weeks. The dose-response relationship is clear — higher doses produce greater weight loss, but the difference between 10mg and 15mg is smaller than between 5mg and 10mg.
Tirzepatide 5mg: −15.0% · Tirzepatide 10mg: −19.5% · Tirzepatide 15mg: −20.2% vs. Placebo: −3.1%. The marginal gain from 10mg to 15mg is approximately 0.7 percentage points. Source: Jastreboff et al., NEJM 2022 (SURMOUNT-1).
The 5mg dose: underrated starting point
Many patients and clinicians treat 5mg as merely a stepping stone to higher doses. The SURMOUNT-1 data challenges this: 5mg produced 15.0% average body weight loss over 72 weeks — a clinically significant result that exceeds semaglutide’s 14.9% average at its maximum 2.4mg dose. For patients who achieve adequate response at 5mg with good tolerability, remaining at this dose is a legitimate long-term strategy. The guiding principle for tirzepatide dosage: reach the lowest effective maintenance dose, not the highest available.
The 10mg dose: primary therapeutic target for most patients
In clinical practice, the 10mg tirzepatide dosage represents the most common maintenance target. It delivers near-maximum efficacy (within 0.7% of the 15mg result) at a level most patients tolerate well after the escalation phase. Physicians typically evaluate response at 10mg before deciding whether to advance to 12.5mg or 15mg.
When 15mg is appropriate
Advancing the tirzepatide dosage to 15mg is appropriate when a patient has reached 10mg, tolerated it well, but has not achieved adequate clinical response — typically defined as less than 5% body weight loss after 12 weeks at the current therapeutic dose. Patients with BMI ≥40 or significant metabolic comorbidities may also benefit from the marginal additional efficacy at 15mg.
Dosing for Type 2 Diabetes vs. Weight Loss
The tirzepatide dosage schedule is identical for both indications — the difference lies in what clinical outcome is targeted and how response is defined. Understanding this distinction is important: the same tirzepatide dosage produces different clinical targets depending on whether the indication is weight management (Zepbound) or type 2 diabetes (Mounjaro).
| Parameter | Weight Management (Zepbound) | Type 2 Diabetes (Mounjaro) |
|---|---|---|
| Starting dose | 2.5 mg weekly | 2.5 mg weekly |
| Escalation interval | Every 4 weeks | Every 4 weeks |
| Maximum dose | 15 mg weekly | 15 mg weekly |
| Primary response metric | % body weight loss; ≥5% at 12 weeks = adequate response | HbA1c reduction and fasting glucose; weight is secondary |
| Non-response threshold | <5% weight loss after 12 weeks → reassess or escalate | Inadequate HbA1c after 3 months → escalate or add agent |
| Hypoglycemia risk | Low in non-diabetic patients | Higher — especially with concurrent insulin or sulfonylureas; requires dose adjustment before starting |
| Maintenance approach | Lowest effective dose (may stay at 5mg or 10mg) | Titrate to glycemic target; may need maximum dose for HbA1c control |
When to Slow or Pause Escalation
The FDA-approved tirzepatide dosage schedule specifies a minimum of 4 weeks at each dose level, not a maximum. Slowing escalation is clinically appropriate — and often preferable — in the following situations:
- Persistent nausea or vomiting: If GI symptoms from the current dose have not resolved by the end of 4 weeks, staying for another 4 weeks gives the body more time to adapt before the next dose increase.
- Inadequate caloric intake: If nausea is causing intake below approximately 1,000–1,200 kcal/day consistently, further escalation will deepen the deficit to a clinically unsafe level. Nutritional support takes priority.
- Accelerated weight loss already occurring: Patients losing more than 1–1.5% body weight per week at the current dose may not need to escalate. Losing weight too quickly carries its own risks, including lean mass loss and gallstone formation.
- Intercurrent illness or surgery: Pause escalation during acute illness, surgery, or recovery when oral intake is compromised.
Practical Tirzepatide Dosage Management: Timing, Storage, and Missed Doses
Injection timing
Tirzepatide can be injected at any time of day, with or without food, on a consistent day each week. The most practical strategy for minimising nausea — particularly during escalation — is to inject at bedtime on the same day each week. This allows the patient to sleep through the peak plasma concentration window when GI effects are most prominent. For full guidance on injection technique and site rotation, see our starting dose guide.
What to do if you miss a dose
If the missed injection is within 4 days of the scheduled day, administer it as soon as remembered and resume the regular weekly schedule from that new day. If more than 4 days have elapsed, skip the missed dose entirely and resume the next scheduled injection on the original day. Never administer two doses in the same week — do not double-dose to compensate for a missed injection, as this significantly increases the risk of adverse effects.
Storage requirements
Tirzepatide auto-injector pens must be stored in the refrigerator at 36–46°F (2–8°C). Pens can be stored at room temperature (up to 86°F / 30°C) for a maximum of 21 days. Do not freeze. Allow the pen to reach room temperature for approximately 30 minutes before injecting.
Compounded versions of tirzepatide were legally available during the FDA-declared drug shortage (2022–2024). The FDA removed tirzepatide from the shortage list in early 2025, significantly restricting legal compounding. Compounded formulations are not FDA-approved and have not undergone the safety, efficacy, and quality review of branded Zepbound or Mounjaro. If you are using a compounded product, verify that it comes from an FDA-registered 503A or 503B pharmacy under a valid physician prescription.
Tirzepatide and Other Medications: Key Interactions
The tirzepatide dosing schedule interacts with several medication classes through a shared mechanism: tirzepatide slows gastric emptying, which reduces the absorption rate of orally administered medications. This is clinically relevant for drugs with narrow therapeutic windows or time-sensitive absorption requirements.
- Oral contraceptives: Slowed gastric emptying may reduce absorption of oral hormonal contraceptives. An additional non-oral contraceptive method is recommended for the first 4 weeks after each dose escalation, consistent with FDA prescribing guidance.
- Narrow therapeutic window medications (warfarin, levothyroxine, cyclosporine): Monitor levels more closely during the escalation phase.
- Insulin and sulfonylureas: Dose reduction required at initiation to prevent hypoglycemia in diabetic patients — see warning box above.
- Alcohol: Worsens GI side effects and independently suppresses GI motility. Minimise intake, particularly during escalation.
For a full breakdown of tirzepatide’s side effect profile at each dose level, see our complete guide to tirzepatide side effects. For compliance requirements, the black box warning in full, and telemedicine prescribing details, see our guide on safe use of tirzepatide for weight loss.
Getting Started with a Supervised Tirzepatide Protocol
Tirzepatide is a prescription medication requiring physician evaluation before initiation. Selecting the appropriate tirzepatide dosage — starting dose, escalation pace, and long-term maintenance target — is part of this assessment and requires review of medical history, baseline labs, contraindications, and current medications.
Advanced TRT Clinic provides telemedicine-based evaluation for GLP-1 and dual agonist weight management programmes. Our physicians determine clinical eligibility, set an appropriate escalation plan, and monitor your response through regular follow-up. Learn more about our Weight Loss programme →
